Abstract
Fetal drug therapy represents an exciting new area ofclinical pharmacology. Dynamic changes in the MPFU throughout-pregnancy create a complex physiologic situation that precludes easy predictions of the extent of maternal-fetal drug transfer. Isolated measurements of single pairs of maternal and fetal drug concentrations add little quantitative information about the extent of maternal-fetal drug transfer. More extensive serial measurements of maternal and fetal drug concentrations after empiric treatment of fetal arrhythmias are needed to improve our understanding of the pharmacologic factors contributing to success or failure of the therapy. Such data about maternal-fetal drug transfer may guide clinicians and pharmacologists toward more effective drug administration to improve our success with fetal therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
